SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is seeing significant downward pressure driven by market apprehension surrounding Donald Trump's extended and often incoherent public address, where his discussion of tariffs and Greenland policy raises concerns about global trade stability. Community sentiment is deeply divided, with many expressing alarm over potential economic repercussions while a subset anticipates a swift "buy the dip" recovery from the current volatility.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending amidst significant market volatility, fueled by discussions surrounding former President Trump's public statements on geopolitical issues, including Greenland and proposed tariffs, which are sparking international concern and market reactions. Community chatter is highly polarized, with supporters pointing to a new digital token initiative as a potential short squeeze catalyst, while critics link the former President's rhetoric to broader market instability and question the stock's underlying value.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is highly active amidst intense discussions fueled by geopolitical developments, specifically related to rhetoric from Davos concerning Greenland and potential tariffs impacting European allies. Community sentiment is bifurcated, with many anticipating continued declines from global instability and upcoming interest rate decisions, while a significant portion of traders are actively buying the dip, expecting a customary market rebound despite the contentious headlines.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending following a significant non-exclusive licensing agreement with Pfizer for its Matrix-M adjuvant technology, widely seen by the community as a validation of its core platform. This development has fueled expectations of further partnerships and a potential short squeeze, with many closely watching how management addresses continued activist investor pressure for enhanced shareholder value.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is trending dramatically after announcing promising Phase 1 clinical trial results for its oral drug, soquelitinib, treating moderate to severe atopic dermatitis with strong efficacy and a favorable safety profile. The market is actively discussing the drug's potential, especially for patients resistant to current therapies, driving speculation of significant upside and a short squeeze, though some caution against the early trial stage and potential dilution.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is a focal point of market discussion after recently upgrading its bid for Warner Bros. Discovery assets to an all-cash offer, a strategic move generating debate about its long-term growth prospects ahead of the upcoming earnings report. Community sentiment is sharply divided, with many seeing the stock as oversold and ripe for a rebound, while others express caution regarding the deal's implications and broader market headwinds.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple (AAPL) is currently experiencing highly polarized community sentiment, with many expressing frustration over its recent price decline, perceived lack of AI innovation, and broader market weakness. However, a strong counter-narrative highlights the stock as deeply oversold with historically low RSI levels, presenting a significant "buy the dip" opportunity ahead of its anticipated strong holiday quarter earnings. Geopolitical tensions and ongoing tariff discussions are further fueling volatility and shaping investor outlook on the tech giant.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is experiencing a surge in attention following a pivotal FDA meeting for its ANKTIVA bladder cancer treatment, where regulators reportedly indicated no requirement for new clinical trials and requested additional data for submission within 30 days. This news has ignited strong community discussion, with investors buzzing about a potential short squeeze and highlighting ANKTIVA's broad therapeutic promise across various cancer indications. The stock's robust performance amid a challenging market is drawing significant interest, as many anticipate further positive developments and substantial long-term growth for this biotech company.

ProShares Trust - ProShares Ultra VIX Short-Term Futures ETF 1.5x Shares

ProShares Ultra VIX Short-Term Futures ETF

UVXY is trending amid intensified geopolitical rhetoric and upcoming central bank decisions, driving speculation for a potential surge in market volatility. While some traders anticipate significant upward movement, the community largely discusses its inherent decay, making it a popular instrument for short-selling and a challenging long-term hold. This highlights the ongoing tug-of-war between event-driven fear and the structural nature of volatility products.

Top Wealth Group Holding Ltd. operates as a holding company, which provides caviar and caviar-based gourmet products. It focuses on supplying sturgeon caviar to customers under its own brand, Imperial Cristal Caviar. The company was founded by Kim Kwan Kings Wong on February 1, 2023 and is headquartered in Hong Kong.

Top Wealth Group Holding Ltd. - Ordinary Shares - Class A

Top Wealth Group Holding Ltd.

Top Wealth Group Holding is trending following news of its strategic acquisition of a luxury wine authentication and trading business, diversifying its market beyond caviar. This has ignited significant discussion among traders, with many anticipating further price movement and highlighting strong volume, while others express concerns about a recent public offering and potential dilution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Short Interest in vTv Therapeutics Inc. (NASDAQ:VTVT) Rises By 62.3%

vTv Therapeutics Inc. (NASDAQ:VTVT - Get Free Report) was the target of a large growth in short interest during the month of December. As of December 31st, there was short interest totaling 27,101...

vTv Therapeutics Inc. (NASDAQ:VTVT) Given Average Recommendation of "Moderate Buy" by Analysts

Shares of vTv Therapeutics Inc. (NASDAQ:VTVT - Get Free Report) have been assigned an average rating of "Moderate Buy" from the five analysts that are presently covering the firm, MarketBeat reports...

vTv Therapeutics (NASDAQ:VTVT) Now Covered by Analysts at TD Cowen

TD Cowen began coverage on vTv Therapeutics in a research report on Monday. They set a "buy" rating and a $67.00 price objective for the company...

This vTv Therapeutics Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

vTv Therapeutics (NASDAQ:VTVT) Upgraded at Wall Street Zen

Wall Street Zen upgraded vTv Therapeutics to a "sell" rating in a report on Saturday...

vTv Therapeutics (VTVT) Upgraded to Buy: Here's What You Should Know

vTv Therapeutics (VTVT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

vTv Therapeutics (NASDAQ:VTVT) Stock Crosses Above Fifty Day Moving Average - Here's What Happened

vTv Therapeutics (NASDAQ:VTVT) Stock Crosses Above 50 Day Moving Average - Here's Why...

vTv Therapeutics (NASDAQ:VTVT) Shares Pass Above 50-Day Moving Average - Here's Why

vTv Therapeutics (NASDAQ:VTVT) Stock Crosses Above 50 Day Moving Average - Time to Sell...

Does vTv Therapeutics (VTVT) Have the Potential to Rally 25.17% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 25.2% in vTv Therapeutics (VTVT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

vTv Therapeutics (NASDAQ:VTVT) Raised to Strong-Buy at BTIG Research

BTIG Research upgraded shares of vTv Therapeutics to a "strong-buy" rating in a report on Tuesday...

vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. Its products target the treatment of central nervous system disorders, diabetes and metabolic disorders, inflammation, and cancer. It offers Azeliragon, TTP399, TTP273, HPP593, HPP737, and the Nrf2/Bach1 program. The company was founded on April 2, 2015 and is headquartered in High Point, NC.

vTv Therapeutics Inc - Ordinary Shares - Class A

Up 10% or more

0% to up 9%

Down 1% to 9%

Down 10% or more

The S&P 500 enters 2026 after a strong run. What kind of return do you expect this year?

How will the S&amp;P 500 perform in 2026?

Current Price	$34.00
Prev Close	$35.59
Open	$35.19
Dividend Yield	0.00%
50-Day Moving Average	$33.08
Beta	0.86
Avg. Volume	12,602.50
PE Ratio	-10.71

52-Week High	$44.00
52-Week Low	$13.46
Market Capitalization	$148.73M
EPS (Annual)	-$3.20
Price to Book	1.99
Revenue Per Employee	$44,217.39
Enterprise Value/EBITDA	N/A

VTVT
vTv Therapeutics Inc - Ordinary Shares - Class A

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest VTVT News

VTVTvTv Therapeutics Inc - Ordinary Shares - Class A